Over 20 Cleansweep Auctions End Tomorrow 06/25 - Bid Now

New MR/ultrasound treatment option for prostate cancer shows successful outcomes

Press releases may be edited for formatting or style | March 21, 2024 MRI Rad Oncology Ultrasound
FAIRFAX, Va. (March 20, 2024)—A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City. The traditional treatment options of radiation or surgery often come with a risk of side effects, including urinary incontinence and erectile dysfunction that cause significant morbidity and adverse lifestyle effects. Researchers said that some patients now have a durable alternative for whole-gland treatment with MRI-guided transurethral ultrasound ablation (TULSA) that does not preclude future treatment with surgery or radiation.

“The success of TULSA represents a revolution in whole-gland treatment for prostate cancer,” said lead author Steven S. Raman, M.D., FASR, FSIR, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA. “Prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetimes. We have more research to do, but if validated, TULSA has the potential to change the standard of care for thousands of men.”

In the TULSA procedure, a small catheter-like device is inserted through the urethra into the prostate. Once there, MRI is used to guide precise positioning of 10 therapeutic ultrasound elements into the prostate. MR thermometry is used to monitor the tissue while heating to more than 55 degrees within the prostate and limiting heat to the sensitive nerves surrounding the prostate as the device rotates around the entire gland. The procedure can be performed in an outpatient or in-patient facility under general or spinal anesthesia in two to three hours.
stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats
According to Dr. Raman, “This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency. The latter are the complications of most prostate cancer therapies that patients hate and often result from a lack of precision in treatment monitoring.”

In the prospective observational study, participants showed improvement in the reduction of the presence of cancer, prostate size and prostate-specific antigen levels (PSA), which are markers for cancer. Cancer was undetectable on follow up biopsy by 76% at one year after TULSA with a decrease in median prostate volume by 92% within one year and a decrease in PSA from 6.3 ng/ml to 0.63 ng/ml at five years.

You Must Be Logged In To Post A Comment